VolitionRx Reports Over 95% Early-Stage Cancer Detection Using Capture-Seq Technology

VolitionRx Limited (NYSE American: VNRX) announced proof-of-concept data from a blinded validation cohort demonstrating over 95% sensitivity for stage I and II cancers with 95% specificity using its Capture-Seq liquid biopsy technology. The study, which included 81 subjects, showed detection rates of 94% for stage I and 96% for stage II cancers, with overall sensitivity of 93% and specificity of 95%, highlighting the technology's potential for early cancer detection.

Volition said Capture-Seq is designed to enrich and purify circulating tumor DNA for analysis and may support applications in multi-cancer early detection and minimal residual disease monitoring. The company noted the technology targets an estimated $36 billion total addressable market and is currently the subject of discussions with potential licensing and diagnostic partners to accelerate development and commercialization.

The announcement represents a significant advancement in liquid biopsy technology, which has been gaining traction as a less invasive alternative to traditional tissue biopsies for cancer detection. High sensitivity and specificity in early-stage cancers are particularly important because early detection dramatically improves treatment outcomes and survival rates. Current screening methods often struggle with detecting cancers at stages I and II, making this development potentially transformative for cancer care.

Volition's technology focuses on epigenetics, specifically analyzing DNA methylation patterns in circulating tumor DNA. This approach differs from genetic mutation-based liquid biopsies and may offer advantages in detecting cancers that don't have easily identifiable genetic mutations. The company's research and development activities are centered in Belgium, with additional facilities in the U.S. and London.

The financial implications are substantial, with the company targeting a $36 billion total addressable market for early cancer detection technologies. This market size reflects both the medical need and economic burden of late-stage cancer diagnosis and treatment. Successful commercialization could significantly impact healthcare costs by enabling earlier intervention when treatments are typically less expensive and more effective.

For further information, visit the company's website at https://volition.com/. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

This press release was distributed through InvestorWire, a specialized communications platform that is one of 75+ brands within the Dynamic Brand Portfolio. For more information about InvestorWire, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by InvestorWire, wherever published or re-published at https://www.InvestorWire.com/Disclaimer.